Related Experiment Video
Updated: Jun 10, 2026
08:57
Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
Published on: October 6, 2019
Interleukin 10 gene polymorphism in Iranian patients with multiple sclerosis
Negar Azarpira1, Afshin Borhani Haghighi, Mehrzad Pourjafar
1Transplantation Research Center, Shiraz University of Medical Sciences, Iran.
Acta Neurologica Taiwanica
|August 18, 2010
Summary
Interleukin-10 (IL-10) gene polymorphisms are not associated with multiple sclerosis (MS) in the Iranian population. This finding suggests IL-10 variants do not influence MS susceptibility or disease progression in this ethnic group.
Area of Science:
- Immunogenetics
- Neuroimmunology
- Human Genetics
Background:
- Interleukin-10 (IL-10) is a cytokine that modulates immune responses, including the inhibition of T-helper 1 (Th1) and T-helper 2 (Th2) cells.
- Genetic variations in the IL-10 promoter region may influence its expression levels and, consequently, immune system regulation.
Purpose of the Study:
- To investigate the association between specific single-nucleotide polymorphisms (SNPs) in the IL-10 promoter gene and the risk of developing multiple sclerosis (MS).
- To determine if IL-10 gene polymorphisms influence disease subtypes or progression in an Iranian MS patient cohort.
Main Methods:
- Genotyping of three IL-10 promoter SNPs (-1082, -819, -592) using Amplification Refractory Mutation System (ARMS) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP).
- Analysis of genetic data from 110 Iranian MS patients and 100 age- and ethnically-matched healthy controls.
Main Results:
- No statistically significant differences were observed in the allelic or genotype frequencies of the studied IL-10 polymorphisms between MS patients and controls.
- IL-10 gene polymorphisms did not show any association with MS susceptibility in the investigated Iranian population.
- Disease course, gender, and progression index did not correlate with the distribution of IL-10 alleles or genotypes.
Conclusions:
- IL-10 promoter polymorphisms are not significantly associated with multiple sclerosis in the Iranian population.
- These genetic variations do not appear to influence MS susceptibility or disease progression in this non-European cohort.
- Further research in diverse ethnic groups may be warranted to fully elucidate the role of IL-10 genetics in MS.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...